|Day Low/High||73.35 / 78.09|
|52 Wk Low/High||9.67 / 78.40|
The South San Francisco, Calif.-based firm said its Phase 3 study of tirasemtiv in patients with amyotrophic lateral sclerosis did not achieve primary or secondary endpoints.
Retrophin (RTRX), the biotech company that used to be run by indicted hedge fund manager Martin Shkreki, provides an interesting investment opportunity.
Here's how to lock in gains on risky small-cap biotechnology stocks.
Only one fund category (of 20) has beaten the S&P 500 over half a decade.
Markets still down at mid-day but up off the lows coinciding with the close of the European stock markets. Following up on my comments on picking up a few more shares earlier today in United Rentals (URI) on recent weakness. The rental side of the h...
Markets have fallen since our last update, with the Dow off triple digits as we are two hours into the trading day. Oil is having a nice day, up approximately 3% and approaching $60 a barrel again on WTI. Not surprisingly, energy sector outperformi...
As always, I am happy to be standing in for Doug Kass today on the Daily Diary (this Friday from sunny Miami). It looks like it will be an up open to talk about based on early market futures. The euro is heading towards its best week in 18 months, e...